Prognostic impact of primary tumour location after curative resection in Stage I-III colorectal cancer: a single-centre retrospective study
CONCLUSIONS: In Stage I-III colorectal cancer without preoperative treatment, our results suggest that the three tumour sites (right-sided colon, left-sided colon or rectum) may have prognostic significance for recurrence-free survival and survival after recurrence, rather than sidedness alone.PMID:38535894 | DOI:10.1093/jjco/hyae035 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Manabu Inoue Yukihide Kanemitsu Shunsuke Tsukamoto Konosuke Moritani Yasuyuki Takamizawa Hiroyuki Daiko Source Type: research

Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022
CONCLUSION: The ASCO/FoCR/FDA task force recommendations were associated with a shift in patterns of brain metastases exclusion criteria from conditionally excluded to not excluded. These findings demonstrate that the cancer clinical trial community has begun to change the way trials are written to be more inclusive.PMID:38537158 | DOI:10.1200/JCO.23.01777 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 27, 2024 Category: Cancer & Oncology Authors: Hong Xiao Riha Vaidya Dawn L Hershman Joseph M Unger Source Type: research

Racial Disparities in Low-Value Care in the Last Year of Life for Medicare Beneficiaries With Neurodegenerative Disease
This study evaluated racial disparities in the utilization of high-value and low-value care in the last year of life among Medicare beneficiaries with dementia or Parkinson disease.METHODS: This was a retrospective, population-based cohort analysis using data from North and South Carolina fee-for-service Medicare claims between 2013 and 2017. We created a decedent cohort of beneficiaries aged 50 years or older at diagnosis with dementia or Parkinson disease. Specific low-value utilization outcomes were selected from the Choosing Wisely initiative, including cancer screening, peripheral artery stenting, and feeding tube pla...
Source: Clinical Colorectal Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Margarethe E Goetz Cassie B Ford Melissa A Greiner Amy Clark Kim G Johnson Brystana G Kaufman Sneha Mantri Ying Xian Richard J O'Brien Emily C O'Brien Jay B Lusk Source Type: research

Racial Disparities in Low-Value Care in the Last Year of Life for Medicare Beneficiaries With Neurodegenerative Disease
This study evaluated racial disparities in the utilization of high-value and low-value care in the last year of life among Medicare beneficiaries with dementia or Parkinson disease.METHODS: This was a retrospective, population-based cohort analysis using data from North and South Carolina fee-for-service Medicare claims between 2013 and 2017. We created a decedent cohort of beneficiaries aged 50 years or older at diagnosis with dementia or Parkinson disease. Specific low-value utilization outcomes were selected from the Choosing Wisely initiative, including cancer screening, peripheral artery stenting, and feeding tube pla...
Source: Clinical Colorectal Cancer - March 25, 2024 Category: Cancer & Oncology Authors: Margarethe E Goetz Cassie B Ford Melissa A Greiner Amy Clark Kim G Johnson Brystana G Kaufman Sneha Mantri Ying Xian Richard J O'Brien Emily C O'Brien Jay B Lusk Source Type: research

The cross talk of ubiquitination and chemotherapy tolerance in colorectal cancer
J Cancer Res Clin Oncol. 2024 Mar 23;150(3):154. doi: 10.1007/s00432-024-05659-9.ABSTRACTUbiquitination, a highly adaptable post-translational modification, plays a pivotal role in maintaining cellular protein homeostasis, encompassing cancer chemoresistance-associated proteins. Recent findings have indicated a potential correlation between perturbations in the ubiquitination process and the emergence of drug resistance in CRC cancer. Consequently, numerous studies have spurred the advancement of compounds specifically designed to target ubiquitinates, offering promising prospects for cancer therapy. In this review, we hig...
Source: Clinical Colorectal Cancer - March 24, 2024 Category: Cancer & Oncology Authors: Ze Rong Kaifeng Zheng Jun Chen Xiaofeng Jin Source Type: research

Curative criteria for endoscopic treatment of colorectal cancer
Best Pract Res Clin Gastroenterol. 2024 Feb;68:101883. doi: 10.1016/j.bpg.2024.101883. Epub 2024 Jan 25.ABSTRACTAs endoscopic treatment enables en bloc resection of T1 colorectal cancers, the risk of recurrence, often assimilated to the risk of lymph node metastases, must be assessed in order to offer patients an additional treatment if this risk is deemed significant. The curative criteria currently used by most guidelines are depth of invasion <1 mm, well or moderately differentiated tumour, absence of lympho-vascular invasion, absence of significant budding and tumour-free resection margins. However, these factors mu...
Source: Clinical Colorectal Cancer - March 24, 2024 Category: Cancer & Oncology Authors: Lucille Qu énéhervé Mathieu Pioche J érémie Jacques Source Type: research

Management of non-curative endoscopic resection of T1 colon cancer
Best Pract Res Clin Gastroenterol. 2024 Feb;68:101891. doi: 10.1016/j.bpg.2024.101891. Epub 2024 Feb 21.ABSTRACTEndoscopic resection techniques enable en-bloc resection of T1 colon cancers. A complete removal of T1 colon cancer can be considered curative when histologic examination of the specimens shows none of the high-risk factors for lymph nodes metastases. Criteria predicting lymph nodes metastases include deep submucosal invasion, poor differentiation, lymphovascular invasion, and high-grade tumor budding. In these cases, complete (R0), local endoscopic resection is considered sufficient as negligible risk of lymph n...
Source: Clinical Colorectal Cancer - March 24, 2024 Category: Cancer & Oncology Authors: Linn Bernklev Jens Aksel Nilsen Knut Magne Augestad Øyvind Holme Nastazja Dagny Pilonis Source Type: research

Patient-Provider Lung Cancer Screening Discussions: An Analysis of a National Survey
CONCLUSION: Despite updated USPSTF recommendations, rates of patient-provider LCS remains low. Multi-level interventions to address barriers to LCS are needed.PMID:38522980 | DOI:10.1016/j.cllc.2024.02.008 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 24, 2024 Category: Cancer & Oncology Authors: Niki Nourmohammadi Trinity Hsiao Pei Liang Gelareh Sadigh Source Type: research

Disparities in Colorectal Cancer Screening Among Asian American Populations and Strategies to Address These Disparities
Clin Gastroenterol Hepatol. 2024 Apr;22(4):679-683. doi: 10.1016/j.cgh.2024.01.001.NO ABSTRACTPMID:38519261 | DOI:10.1016/j.cgh.2024.01.001 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Ishani Shah Andrew J Gawron Kathryn R Byrne John M Inadomi Source Type: research

Immunotherapy Rechallenge After Checkpoint Inhibitor Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review
Clin Colorectal Cancer. 2024 Feb 21:S1533-0028(24)00005-7. doi: 10.1016/j.clcc.2024.01.005. Online ahead of print.NO ABSTRACTPMID:38519390 | DOI:10.1016/j.clcc.2024.01.005 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Dorien Geusens Daan Dierickx Saskia Carton Eric Van Cutsem Jeroen Dekervel Source Type: research

Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer
Clin Colorectal Cancer. 2024 Feb 16:S1533-0028(24)00006-9. doi: 10.1016/j.clcc.2024.02.001. Online ahead of print.ABSTRACTLiquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular landscape of metastatic colorectal cancer (mCRC) is substantially heterogeneous and dynamic over space and time, ctDNA holds significant advantages as a biomarker for this disease. Numerous studies have demonstrated that ctDNA broadly recapitulates the molecular profile of the primary tumor and metas...
Source: Clinical Colorectal Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Laura Roazzi Giorgio Patelli Katia Bruna Bencardino Alessio Amatu Erica Bonazzina Federica Tosi Brunella Amoruso Anna Bombelli Sara Mariano Stefano Stabile Camillo Porta Salvatore Siena Andrea Sartore-Bianchi Source Type: research

Disparities in Colorectal Cancer Screening Among Asian American Populations and Strategies to Address These Disparities
Clin Gastroenterol Hepatol. 2024 Apr;22(4):679-683. doi: 10.1016/j.cgh.2024.01.001.NO ABSTRACTPMID:38519261 | DOI:10.1016/j.cgh.2024.01.001 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Ishani Shah Andrew J Gawron Kathryn R Byrne John M Inadomi Source Type: research

Immunotherapy Rechallenge After Checkpoint Inhibitor Induced Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review
Clin Colorectal Cancer. 2024 Feb 21:S1533-0028(24)00005-7. doi: 10.1016/j.clcc.2024.01.005. Online ahead of print.NO ABSTRACTPMID:38519390 | DOI:10.1016/j.clcc.2024.01.005 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Dorien Geusens Daan Dierickx Saskia Carton Eric Van Cutsem Jeroen Dekervel Source Type: research

Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer
Clin Colorectal Cancer. 2024 Feb 16:S1533-0028(24)00006-9. doi: 10.1016/j.clcc.2024.02.001. Online ahead of print.ABSTRACTLiquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular landscape of metastatic colorectal cancer (mCRC) is substantially heterogeneous and dynamic over space and time, ctDNA holds significant advantages as a biomarker for this disease. Numerous studies have demonstrated that ctDNA broadly recapitulates the molecular profile of the primary tumor and metas...
Source: Clinical Colorectal Cancer - March 22, 2024 Category: Cancer & Oncology Authors: Laura Roazzi Giorgio Patelli Katia Bruna Bencardino Alessio Amatu Erica Bonazzina Federica Tosi Brunella Amoruso Anna Bombelli Sara Mariano Stefano Stabile Camillo Porta Salvatore Siena Andrea Sartore-Bianchi Source Type: research

Serrated adenocarcinoma of sigmoid colon with mismatch repair protein-proficient phenotype: Histopathological recognition of a new subtype of colorectal adenocarcinoma
Clin Case Rep. 2024 Mar 19;12(3):e8669. doi: 10.1002/ccr3.8669. eCollection 2024 Mar.ABSTRACTSerrated adenocarcinoma is a distinct subtype of colorectal carcinoma characterized by unique histological and molecular features. Here we present a case study of a 58-year-old female patient who presented with generalized weakness, abdominal discomfort, and per-rectal bleeding. This case report highlights the importance of understanding the histopathological features of serrated adenocarcinoma for accurate diagnosis which has impact on further management.PMID:38510231 | PMC:PMC10950788 | DOI:10.1002/ccr3.8669 (Source: Clinical Colorectal Cancer)
Source: Clinical Colorectal Cancer - March 21, 2024 Category: Cancer & Oncology Authors: Diksha Karki Sajan Ngakhusi Source Type: research